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Short Communication
Hypercalcaemia and in vitro osteolysis associated with
xenografts of squamous carcinomas of the tongue
S.-W. Tsao, J.F. Burman & R.L. Carter
Institute ofCancer Research and Royal Marsden Hospital, Sutton, Surrey, SM2 5PX.
It was previously reported that squamous
carcinomas from several sites in the head and neck
resorb bone in vitro by activating osteoclasts (Tsao
et al., 1981). Preliminary bioassays indicated that
these tumours contained increased amounts of
"prostaglandin-like materials" (Bennett et al.,
1980) and subsequent work confirmed that a
mixture of indomethacin-sensitive prostaglandins
(mainly E2) and non-prostaglandin osteolysins was
released by squamous carcinomas and their
associated stroma (Tsao et al., 1981; 1983,
submitted for publication). Xenografts have been
grown from some of our established squamous
carcinoma cell lines (Easty et al., 1981a, b) and this
report describes the effects of such xenografts on
plasma calcium levels in the host and their
osteolytic activity in vitro.
The xenografts were grown from 2 cell lines from
squamous carcinomas of the tongue: Cell line
LICR/HN 5 was derived from a primary tumour
and LICR/HN 6Rt from a locally recurrent lesion-
see Easty et al. (1981a, b). The recipients were
female mice of an inbred stain CBA/CaOla (Olac
1976 Ltd), immunosuppressed according to the
method of Miller et al. (1963) with some
modifications (Steel et al., 1978). Tumour
xenografts were implanted s.c. into the flanks and
passaged as solid fragments. Growth of the
xenografts was followed by weekly measurement of
external tumour diameters with vernier callipers.
The wt of each animal was recorded and small
samples (100-200pl) of blood were collected from
the orbital venous plexus.
Plasma calcium levels were determined in
duplicate with a Corning 940 calcium analyser and,
in later experiments, on a Technicon Auto-analyser
II together with inorganic phosphate, alkaline
phosphatase and urea. Albumin levels were
determined manually using the bromcresol green
method.
Bone resorption assays were based on the
standard procedure described by Reynolds (1968).
45Ca-labelled calvaria were dissected from neonatal
mice (5-7 days) and cultured in vitro. Paired half-
calvaria were used in the assay and bone resorptive
activity was measured by the release of radioactive
45Ca from the prelabelled bone into the culture
medium during a 3 day incubation period. The in
vitro osteolytic activity of the xenografts was
examined by culturing tumour fragments in
modified Bigger's medium supplemented with 5%
heat inactivated rabbit serum and antibiotics (Tsao
et al., 1981). Cell-free supernatants after 3 days
incubation were prepared by filtration (0.45,um
Millipore filter) and used as test medium in bone
cultures. The osteolytic activity was expressed in the
usual way as a ratio of release of 45Ca from
labelled bone in test and control cultures. Four
pairs of test and control bone cultures were used in
each determination. Prostaglandins present in
culture media were purified by thin-layer
chromatography (Eastman & Dowsett, 1976) and
quantitated by radio-immunoassay using two
antisera raised separately against PGE2 and PGF2.
from Steranti laboratories and 3H-labelled PGE2
(16OCimM-1) and PGF2a (80CimM 1) from
Amersham International Ltd.
The growth rate of the 2 xenografts was
consistent, and transplantation was usually carried
out at 6-8 week intervals when the tumour
measured 1.5 cm in diameter. Both grafts formed
circumscribed nodules and never showed signs of
local invasion or dissemination. Their histological
features remained closely similar to those of the 2
squamous carcinomas from which they were
derived. Serial estimations of plasma calcium
(Corning 940 calcium analyser) were made and
clear differences emerged between animals whose
grafts grew progressively compared with those
where the tumours failed to develop. Initial results
from 10 tumour-implanted mice are shown in
Figures 1 and 2. With both LICR/HN5 (Figure 1)
and LICR/HN 6Rt (Figure 2) progressively growing
tumours were associated (after about one month)
with parallel rises in plasma calcium levels. No
changes in plasma calcium were observed in mice
whose grafts did not grow.
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Figure 1 Effects of xenografted squamous carcinomas
of tongue (LICR/HN5) on plasma calcium levels in
recipient animals. (a) Changes in plasma calcium
levels; (b) Growth rate of xenografted tumours-l &
2: mice with progressively growing tumours; 3 & 4
mice with tumours which failed to grow.
More plasma was collected from additional mice
with progressively growing tumours and from
ungrafted control mice and estimations of calcium,
inorganic phosphate, alkaline phosphatase, albumin
and urea were made (Table I). Hypercalcaemia was
again confirmed in animals with progressively
growing xenografts using another procedure
(Technicon Autoanalyser II instead of the Corning
940 calcium analyser); inorganic phosphate levels
tended to be low. Concentrations of alkaline
phosphatase, albumin and urea were similar in both
groups of animals. The parathyroid glands were
checked in all mice at necropsy. No glandular
enlargement and no histological evidence of
hyperparathyroidism was observed in tumour-
bearing animals. Immunoreactive parathyroid
hormone levels were not measured.
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Figure 2 Effects of xenografted squamous carcinomas
of tongue (LICR/HN6Rt) on plasma calcium levels in
recipient animals. (a) Changes in plasma calcium
levels; (b) Growth rate of xenografted tumours &
2: mice with progressively growing tumours; 3 & 4
mice with tumours which failed to grow.
The possibility that the hypercalcaemia might be
due to prostaglandins released by the tumours was
examined by investigating the potential blocking
effects of indomethacin. Separate experiments were
made in which the drug was given orally to mice
with established LICR/HN 5 tumours and
intraperitoneally to mice with established
LICR/HN 5 and LICR/HN 6Rt tumours, using
doses of 5 mg in 100ml drinking water and
0.5mgml- 1 in 0.2ml physiological saline
respectively. No significant effects were seen: the
tumours grew and plasma calcium levels continued
to rise.
In vitro bone resorbing activities of the two
xenografts are shown in Table II. The results are
expressed conventionally as the ratio of 45Ca release
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Table I Effects of growth of two xenografted tumours (LICR/HN5 & LICR/HN6Rt) on the levels of plasma
calcium, inorganic phosphate, urea, albumin and alkaline phosphatase in host animals
Inorganic Alkaline
Xenograft Mouse Mean tumour Calcium phosphate Urea Albumin phosphatase
tumour no. diameter (mm) (mg100 ml-1) (g1 1) (mg 100ml-1) (g11) (iu1-)
LICR/HN 5
(passage 7) 1+2 19.8 13.5 3.4 38.4 24.0 112
3+4 19.6 12.8 3.2 91
5+6 17.3 12.5 3.9 34.8 23.0 93
7+8 19.3 11.1 3.8 27.0 24.0 97
LICR/HN6Rt
(passage 7) 9+10 19.8 11.6 3.4 31.0 21.0 75
Control
(no tumour) 11+12 9.3 4.7 33.0 24.0 102
13+ 14 9.0 5.9 34.0 23.0 100
The plasma from pairs of mice with tumour grafts of similar size was pooled for these estimations.
Table II In vitro bone resorption by freshly excised
xenografted tumours
Passage 45Ca release:
Xenografted tumour number (Test/control) ApH
LICR/HN 5 8 2.22+0.4 0.20
LICR/HN 5 9 1.82+0.07 0.13
LICR/HN6Rt 8 2.37+0.18 0.08
LICR/HN6Rt 9 2.36+0.11 0.12
ApH =pH (control medium)-pH (test medium)
Each test/control ratio is mean +s.e. of 4 pairs of test
and control cultures.
et al., 1981). Osteolysis was not significantly
inhibited by adding indomethacin (1 jgml-1) to
duplicate cultures. Radioimmunoassay of tumour-
conditioned media revealed only small amounts of
prostaglandins-both PGE2 and PGF2a being
<5ngml- .
Two xenografted squamous carcinomas of the
tongue have been shown to induce hypercalcaemia
in their animal hosts and to resorb bone in vitro.
The hypercalcaemia develops in association with
progressively growing xenografts which have
reached a size of 1 cm3. Plasma calcium values
then rise in parallel with increasing tumour size.
The parathyroid glands are macroscopically
normal. Spread of tumour into local or distant
bone was never observed, and no gross
abnormalities were seen in the skeleton at autopsy.
Both xenografts are, however, osteolytic in vitro
and the most likely source of the mobilized calcium
is bone. The absence of both in vivo and in vitro
effects of indomethacin and the detection of only
small (<5 ngml-1) amounts of PGE2 and PGF2. in
vitro suggest that the stimuli for calcium release,
both in the intact animal and in tissue culture, are
non-prostaglandin in nature.
Hypercalcaemia in the absence of detectable
skeletal metastases is a well-documented feature of
several forms of malignant disease, and there is
extensive evidence that some tumours elaborate
osteolytic factors which stimulate distant bone
resorption and cause hypercalcaemia. Two
experimental neoplasms, the HSDM1 fibrosarcoma
in mice and the VX2 squamous carcinoma in
rabbits, release large amounts of prostaglandin E2
in vitro and induce a hypercalcaemia which is
reduced by treatment with indomethacin (Tashjian
et al., 1972; Voelkel et al., 1975). In contrast,
Seyberth et al., (1980) found that the Walker
carcinosarcoma 256 provoked hypercalcaemia in
rats which was not lowered by indomethacin given
at doses sufficient to inhibit systemic production of
prostaglandin E2. Clinical observations indicate that
inhibitors of prostaglandin synthesis such as
indomethacin or aspirin are ineffective in the
treatment of hypercalcaemia in most patients with
cancer (Brereton et al., 1974; Seyberth et al., 1975;
Powles et al., 1982); and Tashjian (1978; also
Tashjian et al., 1982) has suggested that probably
< 10% of tumour-associated hypercalcaemias can
be attributed to excessive production of
prostaglandins in the tumour by neoplastic cells
and/or their associated (host) stroma. Non-
prostaglandin hypercalcaemic agents have been
proposed such as parathyroid hormone, "osteoclast106 S.-W. TSAO et al.
activating factor" and certain other chemically ill-
defined products (Mundy et al., 1974a, b; Raisz et
al., 1978; Martin & Atkins, 1979; Josse et al., 1981;
Nimberg et al., 1982) but their role in the
hypercalcaemias of malignant disease is unclear.
Ectopic production of parathyroid hormones by
non-endocrine tumours is rare (Easty & Carter,
1980) and the part played by osteoclast activating
factors and similar agents is likely to remain
confused until their chemical structure is clarified,
assays are available and they can be studied under
in vivo conditions. The nature of the osteolysin(s)
described here is at present unknown.
In summary: s.c. xenografts of 2 squamous
carcinomas of the tongue induce hypercalcaemia in
immunosuppressed CBA/CaOla mice in the absence
of detectable bone invasion. Both xenografts do,
however, resorb bone in vitro. Neither the
hypercalcaemia nor the in vitro osteolysis are
inhibited by indomethacin and levels of
prostaglandins released from xenografts into culture
media are low (PGE2, PGF2, both <5ngml-1).
The bone resorbing factor elaborated by these
xenografts thus appears to be non-prostaglandin in
nature.
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